Overview of RaySearch Laboratories' Performance
RaySearch Laboratories AB (publ) has released its interim report detailing its progress and performance for the second quarter of the year. The report highlights key financial metrics, order intakes, and significant events that demonstrate the company's commitment to innovation in cancer treatment technologies.
Second Quarter Financial Highlights
For the second quarter covering April to June, the company reported an order intake of SEK 241.2 million, compared to SEK 290.3 million in the previous year. This change reflects the company's adaptive business strategy amidst global market fluctuations. The net sales stood at SEK 304.9 million, slightly below the SEK 318.9 million recorded in the prior year.
Operational performance also saw a decline, with an operating profit of SEK 36.4 million down from SEK 79.3 million. The profit after tax was SEK 30.8 million compared to SEK 61.4 million a year ago, and the earnings per share before and after dilution decreased to SEK 0.90 from SEK 1.79.
Cash Flow and Order Backlog
Cash flow from operating activities amounted to SEK 70.6 million, a significant decrease from SEK 154.6 million in the same period last year. As of the end of this quarter, the order backlog was reported at SEK 1,665.3 million, down from SEK 1,790.5 million.
Insights from Half-Year Results
Looking at the half-year results for January to June 2025, RaySearch achieved an order intake of SEK 650.8 million, an increase from SEK 528.8 million. Net sales for this period were SEK 636.6 million, exceeding the SEK 576.1 million from the previous year. Operating profit was reported as SEK 111.2 million compared to SEK 125.1 million, and profit after tax reached SEK 87.6 million, down from SEK 98.1 million. Furthermore, the earnings per share were SEK 2.55 for this half-year, down from SEK 2.86.
Major Events in the Quarter
During the second quarter, several significant milestones were highlighted:
- Odense University Hospital placed an order to enhance automation with the RayStation treatment planning system.
- The launch of RayStation v2025 took place in May, which includes advanced automated treatment planning powered by machine learning and the ECHO algorithm, catering to patients in an upright position.
- RaySearch announced that The Royal Marsden was the first clinic globally to utilize the new adaptive re-planning module in RayStation during online adaptive radiotherapy.
- A groundbreaking clinical milestone was achieved as RayStation facilitated the first accelerator-based BNCT treatments in Europe at a Helsinki University Hospital.
- In June, RayCare v2025 was launched, featuring enhancements that streamline workflows and improve data management across the treatment continuum.
Post-Reporting Developments
In subsequent developments:RaySearch formed a strategic partnership with Radiology Oncology Systems, Inc., focusing on integrating refurbished linear accelerators with advanced software solutions. Additionally, AKSM/Oncology selected RayCare and RayStation for a new cancer center, reflecting the growing adoption of these innovative technologies.
Future Outlook and Innovations
RaySearch Laboratories remains committed to pushing the boundaries of cancer treatment with ongoing innovations in their software solutions. Their continuous development aims to enhance the efficiency and effectiveness of cancer therapies, significantly impacting patient success rates.
Contact Information for Inquiries
For additional information, please contact:
Johan Löf, CEO | Tel: +46 8 510 530 00, e-mail: johan.lof@raysearchlabs.com
Nina Grönberg, CFO | Tel: +46 8 510 530 00, e-mail: nina.gronberg@raysearchlabs.com
Frequently Asked Questions
What were the key financial highlights for RaySearch in Q2 2025?
In Q2 2025, RaySearch reported an order intake of SEK 241.2 million and net sales of SEK 304.9 million, with an operating profit of SEK 36.4 million.
What new technologies did RaySearch launch during the quarter?
RaySearch launched RayStation v2025, which includes advanced automated treatment planning, and RayCare v2025, which enhances clinical workflows and data management.
Where was the first clinical application of RayStation v2025?
The Royal Marsden was the first clinic worldwide to use the new adaptive re-planning module in RayStation during online adaptive radiotherapy.
What recent partnerships has RaySearch established?
RaySearch partnered with Radiology Oncology Systems, Inc. to integrate refurbished linear accelerators with advanced software solutions.
How many clinics worldwide utilize RaySearch software?
RaySearch's software is utilized in over 1,100 clinics across 47 countries, showcasing its global reach and impact on cancer treatment.
